OSIRIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Wolf

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OSIRIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Been Filed Against Osiris Therapeutics, Inc. in the United States District Court for the District of Maryland -- OSIR

NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has commenced in the United States District Court for the District of Maryland against Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (Nasdaq: OSIR ) on behalf all persons or entities who purchased Osiris securities between May 12, 2014 and November 20, 2015, inclusive (the “Class Period”). 

Shareholders who incurred losses on shares purchased within the Class Period are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

If you purchased the shares of Osiris Therapeutics, Inc., you may, no later than January 22, 2016, request that the Court appoint you lead plaintiff of the proposed class.

On November 16, 2015, the Company surprised investors by disclosing that it had “determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenue of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014.”  

Following this news of an accounting restatement, Osiris shares fell, dropping $3.02, or 21.53%, to close at $10.97 on November 17, 2015.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at classmember@whafh.com , or visit our website at www.whafh.com .  All e-mail correspondence should make reference to the “Osiris Investigation.”

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Contact: Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: gstone@whafh.com, donovan@whafh.com or classmember@whafh.com Tel: (800) 575-0735 or (212) 545-4774

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Grupo Simec 2026 Nine-Month Financial Surge Spells Change

Updated Category News Views 64

Sharp Climb in Net Income Sparks Interest Buckle up, folks. Grupo Simec's nine-month results for 2026 are a mixed bag of surprises and steady flows. Let’s break it down: the net income skyrocketed by a whopping 428% compared to the same period last year—jumping from Ps. 763 million to Ps. 4,028 million. That's a solid leap, and it’s largely due to turning a hefty...

Continue Reading
Cloopen Group's Private Transition: What Investors Should Know

Updated Category News Views 121

Cloopen Steps Away from Public Market Scene Here's a tale simmering on the corporate backburner: Cloopen Group Holding Limited, that cloud juggernaut over in China, has gone all private on us. The ink is drying on their merger with SummerX Holdings Limited, under the overarching umbrella of SpringX Holdings. So, now this communications outfit has slipped out of the public...

Continue Reading
LanguageLine AI App Earns Vizient Technology Kudos

Updated Category News Views 0

Tech Talk: LanguageLine's AI App Gains Important Recognition Diving headfirst into the chaotic world of healthcare, LanguageLine's AI Translation App earned a standout accolade. Just announced, it's snagged the Innovative Technology Designation from Vizient, the heavyweight champ in healthcare performance improvement. On the scene since the end of October, they rolled the...

Continue Reading
Core Lab's Quarterly Grit: Navigating a Turbulent Market

Updated Category News Views 71

Core Lab's Quarter in Review With the kind of resilience that makes a trader's hands shake ever so slightly less over a coffee, Core Laboratories Inc. heads into the fourth quarter of 2026. This isn't your typical Wall Street story, that's for sure. Watching a solid player like Core navigate the bumpy roads of today's volatile market reminds me of a...

Continue Reading
Freddy’s Joins Hershey For a Limited-Time Flavor Fest

Updated Category News Views 95

The Sweet Collaboration We Didn't See Coming Well, folks, here's a tasty twist for you—Freddy's Frozen Custard & Steakburgers is cozying up to The Hershey Company to bring a sugar rush to our mundane lives. Starting Nov. 4, they're rolling out a limited-time series of treats so indulgent you'll want to skip straight to dessert. And if that wasn't enough, they're...

Continue Reading
Bloomberg Law Integrates Docket Data with AI Platform

Updated Category News Views 0

Bloomberg Law's Game-Changer for Legal Pros Here's something that'll make legal eagles perk up on this fine day: Bloomberg Law has rolled out a connector for Claude, marrying court dockets and litigation smarts to AI. Let's face it, the legal world always runs on precision and timing above all. So when an integration like this drops, it ain’t just a memo on the office...

Continue Reading
AppLovin Faces Class Action: AI Growth Claims Under Fire

Updated Category News Views 67

AppLovin's AI Jackpot: A Busted Flush? This year's been a rollercoaster at AppLovin Corporation, and not the fun kind. Let me tell ya, investors bought into a dream—a self-sustaining, profit-churning machine based on AI advertising models. Unfortunately, reality came around like a bad penny, and suddenly, their 'virtuous cycle' feels more like a busted flush....

Continue Reading
Genedata's New ELN Transforms Biopharma R&D Workflows

Updated Category News Views 58

Revolutionizing Research with a New Digital Tool Genedata, the brain behind enterprise software for drug discovery, has thrown a curveball into the world of biopharmaceutical research by launching a pioneering electronic lab notebook (ELN). This isn’t just another software update; it's a complete shift in how R&D workflows are structured and maintained. With an...

Continue Reading
J.H. Strain & Sons' Asset Sale Seals a New Era

Updated Category News Views 59

Texan Legacy Bows Out of the Asphalt Game Here's a fresh chapter in the world of road construction that'll have folks in the industry doing a double-take. Elder Bray & Bankler, a bigwig among corporate law circles, has been guiding this tale. They've shepherded J.H. Strain & Sons through selling off its asphalt manufacturing and construction assets to none other than...

Continue Reading
Motiva's Q3 2026 Results: Strategic Moves Drive Growth

Updated Category News Views 0

Strategic Transactions and Financial Highlights Motiva's third quarter of 2026 shows a company not just coasting but recalibrating its trajectory. Big moves had ripple effects on their financial landscape, most notably their sale of the Airport Platform, concluded for a hefty R$5.2 billion. Their portfolio's trimming isn't just a garage sale but a thought-out step...

Continue Reading

Top 5 Most Recently Viewed Articles

Lilly Flexes Oncology Muscle at 2026 ASCO Meet

Updated Category News Views 19

Lilly's Pipeline Gets the Spotlight With the ASCO conference kicking off in Chicago this year, Eli Lilly (NYSE: LLY) is coming in guns blazing. The company's oncology roster is vast and spread across a variety of tumor types and treatment modalities. This year's presentations are dripping with promise. You got Retevmo leading the charge in a plenary session, joined by...

Continue Reading
David Brenneman Strengthens Antitrust Practice at Latham

Updated Category News Views 212

David Brenneman Joins Latham & Watkins Latham & Watkins LLP is excited to announce a significant addition to their Antitrust & Competition Practice. Renowned antitrust lawyer David Brenneman has joined their Washington, D.C. office as a partner. Brenneman brings considerable expertise in managing the antitrust aspects of various mergers and acquisitions, enhancing the...

Continue Reading
Join the Class Action for Viatris Inc.: Important Updates

Updated Category News Views 419

Understanding the Viatris Class Action Opportunity Attention, investors! If you've purchased securities of Viatris Inc. (NASDAQ: VTRS), this is a critical time for you. The Rosen Law Firm, renowned for advocating investor rights globally, is reaching out to individuals who bought Viatris stocks during an identified time frame. Having knowledge of these events is essential...

Continue Reading
Transformative Health Education: Empowering Future Generations

Updated Category News Views 120

Understanding the Growing Health Crisis A crisis is quietly unfolding in classrooms across the nation: rising rates of preventable chronic illnesses, mental health struggles, and pervasive health illiteracy are significantly impacting the wellness of today's youth. In the face of these alarming statistics, Know Yourself Academy emerges as a beacon of hope, aiming to...

Continue Reading
Free Guide by Pacific Mind Health Eases Anxiety

Updated Category News Views 11

Wrestling with Your Inner Spotlight? Pacific Mind Health Steps In There's a good chance most of us have been there—sweatin' the small stuff like we're the star attraction in the circus of life, convinced everyone else is watching as we trip over our own shoelaces. Well, don't sweat it. Pacific Mind Health has jumped in to lend a hand with some real tools to shake off...

Continue Reading